TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28615258

Group type: EXPERIMENTAL
Intervention: Package of health and nutrition interventions (lipid nutrient supplement, deworming medication, zinc supplementation, bed net, malaria chemoprophylaxis)
Number of subjects: 1383

Group type: COMPARATOR
Intervention: Control group (routine health and nutrition counseling only)
Number of subjects: 1383

Group type: EXPERIMENTAL
Intervention: Both intervention and control groups
Number of subjects: 1383
Study: 25783161

Group type: EXPERIMENTAL
Intervention: Beclomethasone (40 μg twice daily)
Number of subjects: 288
Study: 24025630

Group type: EXPERIMENTAL
Intervention: Low-fat yogurt mixed with a fat-free aroma extract of olive oil
Number of subjects: 11

Group type: COMPARATOR
Intervention: Plain low-fat yogurt
Number of subjects: 11
Study: 21410628

Group type: EXPERIMENTAL
Intervention: Linagliptin plus pioglitazone (30 mg pioglitazone plus 5 mg linagliptin)
Number of subjects: 389

Group type: COMPARATOR
Intervention: Placebo plus pioglitazone (30 mg pioglitazone plus placebo)
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Linagliptin plus pioglitazone
Number of subjects: 389

Group type: COMPARATOR
Intervention: Placebo plus pioglitazone
Number of subjects: 389
Study: 18376230

Group type: EXPERIMENTAL
Intervention: Curative surgery
Number of subjects: 193

Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 193

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 193

Group type: COMPARATOR
Intervention: Overall cohort
Number of subjects: 193
Study: 16391331

Group type: EXPERIMENTAL
Intervention: Vitamin B12 for 2 months followed by folic acid for 2 months
Number of subjects: 200

Group type: COMPARATOR
Intervention: Folic acid for 2 months followed by vitamin B12 for 2 months
Number of subjects: 200
Study: 12673681

Group type: EXPERIMENTAL
Intervention: Peptide MAGE‐A12:170‐178 administered subcutaneously in incomplete Freund's adjuvant (IFA), either every week or every 3 weeks for 4 cycles.
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Peptide MAGE‐A12:170‐178
Number of subjects: 9
Study: 10780138

Group type: EXPERIMENTAL
Intervention: Telephone-administered cognitive-behavioral therapy (CBT) - Coping with MS (CMS)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Usual-care control (UCC)
Number of subjects: 32
Study: 8776821

Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC) 30 mg intravesical instillations weekly for 8 weeks, followed by monthly maintenance doses for 12 months
Number of subjects: 208

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 208
Study: 1346807

Group type: EXPERIMENTAL
Intervention: Zidovudine
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 6844410

Group type: EXPERIMENTAL
Intervention: Maximal inspiratory breathing exercises
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Incentive spirometry
Number of subjects: 49

Group type: COMPARATOR
Intervention: Early mobilization
Number of subjects: 49
Study: 31985380

Group type: EXPERIMENTAL
Intervention: Maqliasa capsules (2 capsules t.i.d.) for 28 days
Number of subjects: 13
Study: 30724658

Group type: EXPERIMENTAL
Intervention: JVC‐001
Number of subjects: 100

Group type: COMPARATOR
Intervention: MR with monovalent mumps vaccine (Hoshino strain)
Number of subjects: 100
Study: 29880238

Group type: EXPERIMENTAL
Intervention: Amisulpride (100 mg daily)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Amisulpride (continued treatment)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo (switched from amisulpride)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 101
Study: 27368062

Group type: EXPERIMENTAL
Intervention: HbA1c criteria
Number of subjects: 17971

Group type: COMPARATOR
Intervention: FPG criteria
Number of subjects: 17971

Group type: EXPERIMENTAL
Intervention: HbA1c alone
Number of subjects: 17971

Group type: COMPARATOR
Intervention: FPG alone
Number of subjects: 17971

Group type: EXPERIMENTAL
Intervention: HbA1c
Number of subjects: 17971

Group type: COMPARATOR
Intervention: FPG
Number of subjects: 17971
Study: 24722047

Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Botulinum toxin type A
Number of subjects: 30
Study: 22491507

Group type: EXPERIMENTAL
Intervention: Viewing a training video on empowerment
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (no video)
Number of subjects: 43
Study: 20563965

Group type: EXPERIMENTAL
Intervention: DemTect-B
Number of subjects: 80

Group type: COMPARATOR
Intervention: DemTect-A
Number of subjects: 80
Study: 17036029

Group type: EXPERIMENTAL
Intervention: Oral erythromycin 1 mg/kg every 8 h
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 60
Study: 15766294

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 384
Study: 16920758

Group type: EXPERIMENTAL
Intervention: TV group (passive distraction with a TV cartoon)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: M group (active distraction by mothers)
Number of subjects: 69

Group type: COMPARATOR
Intervention: C group (control without distraction)
Number of subjects: 69
Study: 11134689

Group type: EXPERIMENTAL
Intervention: Ambient odor of orange
Number of subjects: 72

Group type: COMPARATOR
Intervention: No odor (control group)
Number of subjects: 72
Study: 9156785

Group type: EXPERIMENTAL
Intervention: TCV-309 (1.0 mg/kg twice daily for 7 days)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: TCV-309
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 1638191

Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 6240787

Group type: EXPERIMENTAL
Intervention: 2 g of spectinomycin intramuscularly
Number of subjects: 200

Group type: COMPARATOR
Intervention: 2.5 g of thiamphenicol (500 mg intramuscularly after oral 2 g)
Number of subjects: 200
Study: 30472681

Group type: EXPERIMENTAL
Intervention: Prucalopride (1-5 mg/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Abdominal VNS
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham/Placebo
Number of subjects: 30
Study: 29364495

Group type: EXPERIMENTAL
Intervention: L. plantarum P17630 (5x10^9 CFU/capsule)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 25609451

Group type: EXPERIMENTAL
Intervention: Concurrent 3D-CRT/IMRT plus FOLFOX regimen
Number of subjects: 110
Study: 23851593

Group type: EXPERIMENTAL
Intervention: Predefined biochemical profile
Number of subjects: 191

Group type: COMPARATOR
Intervention: Physician discretion
Number of subjects: 191
Study: 22648705

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 59
Study: 20435876

Group type: EXPERIMENTAL
Intervention: Microfracture
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Osteochondral autograft transfer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Autologous chondrocyte implantation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgical interventions
Number of subjects: 0
Study: 18833117

Group type: EXPERIMENTAL
Intervention: Atomoxetine (strattera) in daily dosage 0.8‐1.2 mg/kg as a monotherapy for 6 weeks
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Piracetam as a monotherapy in daily dosage 50‐70 mg/kg for 6 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: No pharmacological therapy
Number of subjects: 42
Study: 16019374

Group type: EXPERIMENTAL
Intervention: Pomeroy technique tubal ligation
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (age-matched women)
Number of subjects: 108
Study: 11921128

Group type: EXPERIMENTAL
Intervention: Suspension (2.5 mg doses)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Tablet (25 mg doses)
Number of subjects: 40
Study: 9885797

Group type: EXPERIMENTAL
Intervention: Ondansetron (acute treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ondansetron (chronic administration)
Number of subjects: 0
Study: 7720151

Group type: EXPERIMENTAL
Intervention: Fentanyl 10 micrograms.kg‐1 before induction of anaesthesia (FA)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Sufentanil 1 micrograms.kg‐1 before induction of anaesthesia (SA)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Fentanyl after removal of the uterus (FC)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Fentanyl after peritoneal incision (FB)
Number of subjects: 85
Study: 30737622

Group type: EXPERIMENTAL
Intervention: Full-thickness skin graft (FTSG)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Synthetic mesh
Number of subjects: 52
Study: 28707173

Group type: EXPERIMENTAL
Intervention: Individually adjusted PEEP levels
Number of subjects: 37

Group type: COMPARATOR
Intervention: Standard ventilator regimen
Number of subjects: 37
Study: 27452327

Group type: EXPERIMENTAL
Intervention: Hypertensive patients
Number of subjects: 170

Group type: COMPARATOR
Intervention: Non-dippers (NT-ND)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Non-dippers (HT-ND)
Number of subjects: 170
Study: 25365688

Group type: EXPERIMENTAL
Intervention: Specificity induction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control induction
Number of subjects: 0
Study: 22320335

Group type: EXPERIMENTAL
Intervention: Increasing the availability of lower-calorie products in vending machines
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Labeling products
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Reducing the price of lower-calorie products
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Combination of availability, labeling, and price reduction
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 28
Study: 18806910

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT) and lifestyle advice (n = 23)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group receiving a lifestyle advice sheet (n = 24)
Number of subjects: 47
Study: 17710290

Group type: EXPERIMENTAL
Intervention: OFD + EMP
Number of subjects: 13

Group type: COMPARATOR
Intervention: OFD
Number of subjects: 13
Study: 15190044

Group type: EXPERIMENTAL
Intervention: Supplementation with mixed fruit and vegetable juice concentrates
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 11593992

Group type: EXPERIMENTAL
Intervention: Press-coated, time-controlled release tablets containing pseudoephedrine hydrochloride
Number of subjects: 8
Study: 9519217

Group type: EXPERIMENTAL
Intervention: Hypo-osmolar aerosol (ultrasonically nebulized distilled water, output 2 ml/min-1)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 24
Study: 7863140

Group type: EXPERIMENTAL
Intervention: Vaginal application of Lactobacillus casei v. rhamnosus twice weekly
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 2692521

Group type: EXPERIMENTAL
Intervention: Carbon monoxide (CO) exposure
Number of subjects: 24

Group type: COMPARATOR
Intervention: Clean air exposure
Number of subjects: 24
Study: 1108645

Group type: EXPERIMENTAL
Intervention: Self-medication during hospitalization and as an outpatient
Number of subjects: 48

Group type: COMPARATOR
Intervention: Traditional drug administration during hospitalization and self-medication as an outpatient
Number of subjects: 48
Study: 31983494

Group type: EXPERIMENTAL
Intervention: Oral ondansetron
Number of subjects: 436

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 436
Study: 31134220

Group type: EXPERIMENTAL
Intervention: Dynamic navigation system (surgery performed with navigation system)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Flapless surgery
Number of subjects: 10

Group type: COMPARATOR
Intervention: Open-flap surgery
Number of subjects: 10

Group type: COMPARATOR
Intervention: Piezoelectric tips
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional burs
Number of subjects: 10
Study: 28117614

Group type: EXPERIMENTAL
Intervention: Carboplatin plus vinorelbine (VC)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Gemcitabine (GC)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 52
Study: 25909320

Group type: EXPERIMENTAL
Intervention: Mobile health intervention with additional medication reminders and adherence assessment via text message
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Mobile health intervention
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control condition (standard treatment with naltrexone)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 76
Study: 23447696

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP) treatment
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP) treatment with TMP-SMX prophylaxis
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP) treatment without TMP-SMX prophylaxis
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 107
Study: 21269351

Group type: EXPERIMENTAL
Intervention: Percutaneous collagen induction (PCI) - four sessions (4 weeks apart)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 100% TCA CROSS - four sessions (4 weeks apart)
Number of subjects: 30
Study: 18216764

Group type: EXPERIMENTAL
Intervention: Remi-1 group (1 ng x mL(‐1) remifentanil)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Remi-2 group (2 ng x mL(‐1) remifentanil)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Remi-3 group (3 ng x mL(‐1) remifentanil)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Remi-4 group (4 ng x mL(‐1) remifentanil)
Number of subjects: 80

Group type: COMPARATOR
Intervention: All groups (including control)
Number of subjects: 80
Study: 16521223

Group type: EXPERIMENTAL
Intervention: Low central venous pressure (LCVP) maintained at 2‐4 mmHg during hepatectomy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (routine hepatectomy without lowering CVP)
Number of subjects: 50
Study: 12878286

Group type: EXPERIMENTAL
Intervention: Polyurethane condom
Number of subjects: 0

Group type: COMPARATOR
Intervention: Latex condom (Control)
Number of subjects: 0
Study: 11101061

Group type: EXPERIMENTAL
Intervention: rhuIL-10 1 microg/kg daily
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: rhuIL-10 4 microg/kg daily
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: rhuIL-10 8 microg/kg three times per week
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo daily
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo three times per week
Number of subjects: 39
Study: 8820468

Group type: EXPERIMENTAL
Intervention: Oral dolasetron mesylate 50, 100, 150, 200, 250, 300, or 400 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Oral dolasetron mesylate (doses up to 400 mg)
Number of subjects: 120
Study: 1420514

Group type: EXPERIMENTAL
Intervention: 24-hour dietary recalls
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Biochemical assessments
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Food frequency questionnaire
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Plasma beta-carotene levels
Number of subjects: 224
Study: 3975255

Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin granules
Number of subjects: 56

Group type: COMPARATOR
Intervention: Buffered aspirin tablets
Number of subjects: 56

Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 56
Study: 29373334

Group type: EXPERIMENTAL
Intervention: DIVA system (automated vasopressor administration)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Manual vasopressor bolus administration
Number of subjects: 236
Study: 27134127

Group type: EXPERIMENTAL
Intervention: Subxiphoid single‐incision VATS
Number of subjects: 43

Group type: COMPARATOR
Intervention: Intercostal uniport VATS
Number of subjects: 43
Study: 24611925

Group type: EXPERIMENTAL
Intervention: 12-week telephone-based motivational interviewing (MI) intervention to improve physical activity (n = 44)
Number of subjects: 92

Group type: COMPARATOR
Intervention: 12-week wait-list control group (n = 48)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: 12-week telephone-based motivational interviewing (MI) intervention
Number of subjects: 92
Study: 22592048

Group type: COMPARATOR
Intervention: 50.4 Gy in 28 fractions (arm A)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: 50.4 Gy in 28 fractions + endorectal boost (10 Gy in 2 fractions) (arm B)
Number of subjects: 248
Study: 20055898

Group type: EXPERIMENTAL
Intervention: Independent research programme on drugs funded by the Italian Medicines Agency (AIFA)
Number of subjects: 0
Study: 18374405

Group type: EXPERIMENTAL
Intervention: Active immunotherapy with alum-adsorbed grass pollen vaccine (Alutard SQ)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 18
Study: 15878068

Group type: EXPERIMENTAL
Intervention: Phacoemulsification
Number of subjects: 400

Group type: COMPARATOR
Intervention: Small-incision
Number of subjects: 400
Study: 12645994

Group type: EXPERIMENTAL
Intervention: RWJ-270201 (BCX-1812) 100 mg/qd
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: RWJ-270201 (BCX-1812) 200 mg/qd
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: RWJ-270201 (BCX-1812) 200 mg/bid
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: RWJ-270201 (BCX-1812) 400 mg/qd
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: RWJ-270201 (BCX-1812) 800 mg on Day 1 followed by 400 mg on Days 2-5
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: RWJ-270201 (BCX-1812) 800 mg on Days 1-5
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 9796233

Group type: EXPERIMENTAL
Intervention: Speeded response in Task1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unspeeded delayed response in Task1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Faster responses in Task1
Number of subjects: 0
Study: 7641477

Group type: EXPERIMENTAL
Intervention: Alternate flexion and extension splinting
Number of subjects: 68

Group type: COMPARATOR
Intervention: Continuous passive motion
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Osteoarthritic knees
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Rheumatoid knees
Number of subjects: 68
Study: 2515342

Group type: EXPERIMENTAL
Intervention: Anti‐schistosomal drugs plus prednisolone (Group II)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Anti‐schistosomal drugs plus cyclosporine (Group III)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Anti‐schistosomal drugs (Group I)
Number of subjects: 26
Study: 345749

Group type: EXPERIMENTAL
Intervention: Gradual reduction of neuroleptic drugs (mean 75 mg equivalent of chlorpromazine)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Maintained on matched dosages of neuroleptics (mean 150 mg equivalent of chlorpromazine)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Gradual reduction of neuroleptic drugs (mean 8 mg equivalent of chlorpromazine)
Number of subjects: 48
Study: 31118095

Group type: EXPERIMENTAL
Intervention: ENGAGE-MUSIC/SPANISH
Number of subjects: 144

Group type: COMPARATOR
Intervention: ENGAGE-DISCOVERY
Number of subjects: 144
Study: 29622047

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham meditation group
Number of subjects: 0
Study: 27743547

Group type: EXPERIMENTAL
Intervention: TIME intervention (N=22)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Treatment as usual (TAU, N=22)
Number of subjects: 44
Study: 25470078

Group type: EXPERIMENTAL
Intervention: Vaginal electrical stimulation (VES)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 23582830

Group type: EXPERIMENTAL
Intervention: Bilevel positive airway pressure (n=66)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Usual care (n=63)
Number of subjects: 129
Study: 20177118

Group type: EXPERIMENTAL
Intervention: IM IFNbeta‐1a 30 microg once weekly plus placebo (n = 12)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: IM IFNbeta‐1a 60 microg once weekly plus placebo (n = 11)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: IM IFNbeta‐1a 30 microg twice weekly (n = 11)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: IM IFNbeta‐1a 60 microg twice weekly (n = 11)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo twice weekly (n = 22)
Number of subjects: 67
Study: 18950449

Group type: EXPERIMENTAL
Intervention: SGB with 10 administrations of 10 mg levobupivacaine every other day for 10 treatments, followed by one administration per month for 6 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Tramadol 100 mg/day and gabapentin 1800 mg/day orally for 6 months, followed by SGB therapy in the 7th month
Number of subjects: 50
Study: 16669726

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Combined treatment (Dextroamphetamine + Psychotherapy)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Combined treatment (Paroxetine + Psychotherapy)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Medication + Psychological therapy
Number of subjects: 98
Study: 12904810

Group type: EXPERIMENTAL
Intervention: Sildenafil 25 mg tablet
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo tablet
Number of subjects: 60
Study: 10720591

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (50 mg bolus injection followed by 50 mg/h continuous infusion for 3 hours)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 8
Study: 9594180

Group type: EXPERIMENTAL
Intervention: THAM (4 to 5 ml/kg infused intravenously 2 to 3 times daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (no THAM treatment)
Number of subjects: 50
Study: 1549435

Group type: EXPERIMENTAL
Intervention: Preference for tap water
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oddity detection task
Number of subjects: 0